MED3000 for ED: an update

[tonyareias]

Let’s see if it works or not. The FDA tests prove that not powerful as PDE5i but works. If it can only help mild or moderate ED is better than nothing.

[timduncan]

It's a scam. I found this article about Med2005, which is basically Med3000.
As you can read the International Index of Erectile Function (IIEF) score is prior usage 17.1 and after 19.6 and 18.5 for placebo. So going from 17.1 to 19.6 for the Med2005 group is also a placebo-like score. A trial for rubbing toothpaste on your penis would basically give the same scores.
The scores for PDE-5 inhibitors in the clinical trials were much higher.

https://scholar.google.com/scholar?hl=n ... BHZt6Oy0EJ


pieces were sung with great recision anlert. 瀾 sometimes when I meet with such apathy on the pur
TTTS TTS SLLLSTTT
JE Roll made a few remarks on the Tonic Sol-fa||..."," J", ought to be active. Mlany of the D. Methol recºmmenline it it is simplicit: il P-||...... was System. One, I ness. The audience appeared highly gratilied witlu tlu know, is doing well. I have lately visited the tttS ikkS:"":""; 點"":"", 1 classes, which are all taught by unprofessional man
Bekijken op search.proquest.com
Verwante artikelen
sciencedirect.com
Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study
David J Ralph, Ian Eardley, Jorg Taubel, Paul Terrill, Tim Holland
The Journal of Sexual Medicine 15 (2), 167-175, 2018
Background
Current treatments for erectile dysfunction (ED) have some limitations.
Aim
This study evaluated the efficacy and tolerability of MED2005, a 0.2% glyceryl trinitrate topical gel, formulated into an enhanced absorption topical delivery system (DermaSys), administered on demand, in the treatment of ED.
Methods
This randomized, double-blinded, placebo-controlled, phase II crossover trial involved 232 men with ED (231 treated, 230 assessed for efficacy) and their partners. After a 4-week run-in period, patients were randomized to 1 of 2 treatment sequences, MED2005-placebo or placebo-MED2005. Each treatment was given for 4 weeks, separated by a 1-week washout interval. Efficacy was assessed by the International Index of Erectile Function (IIEF), the Sexual Encounter Profile, a Global Assessment Questionnaire (GAQ), and specific questions about the onset and offset of action and treatment preferences (patients and partners).
Outcomes
The primary outcome measure was the IIEF erectile function domain (IIEF-EF) score. Other efficacy assessments were secondary outcomes.
Results
The mean baseline IIEF-EF score was 17.1 (SD = 5.7), and this increased to 19.6 (SD = 7.5) after MED2005 treatment and 18.5 (SD = 6.7) after placebo (P = .0132). Overall, 23.1% of patients showed a clinically relevant (≥4-point) increase in IIEF-EF scores after treatment with MED2005 only compared with 14.5% who responded after MED2005 and placebo, 14.0% who responded after placebo only, and 48.4% who did not respond after either treatment (P = .0272). MED2005 also was associated with significant improvements compared with placebo in the other IIEF domains, and this was consistent with patients’ and partners’ responses to the GAQ. For all assessments, significant effects of MED2005 were seen primarily in patients with mild ED. The start of erection was noticed within 5 and 10 minutes in 44.2% and 69.5%, respectively, of all intercourse attempts with MED2005. Patients and partners showed significant preferences for MED2005 over placebo. The most commonly reported adverse events during MED2005 treatment were headache (patients, n = 18 [7.9%]; partners, n = 3 [1.3%]) and nasopharyngitis (patients, n = 13 [5.7%]; partners, n = 2 [0.9%]).
Clinical Implications
These findings suggest that topical glyceryl trinitrate could be a useful treatment option in ED.
Strengths and Limitations
Strengths of this study include the use of a validated outcome measure. Limitations include the use of only 1 dosage.
Conclusion
Further studies are warranted to investigate the efficacy of topical glyceryl trinitrate to include higher doses, thereby improving clinical significance, especially in cases of moderate and severe ED.
Ralph DJ, Eardley I, Taubel J, et al. Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study. J Sex Med 2018;15:167–175.

for all i know they're not the same thing, med3000 was the "placebo gel" in the med2005 trial.
the poor result compared to placebo its because that wasnt a placebo after all

[Brent1]

It's a scam. I found this article about Med2005, which is basically Med3000.
As you can read the International Index of Erectile Function (IIEF) score is prior usage 17.1 and after 19.6 and 18.5 for placebo. So going from 17.1 to 19.6 for the Med2005 group is also a placebo-like score. A trial for rubbing toothpaste on your penis would basically give the same scores.
The scores for PDE-5 inhibitors in the clinical trials were much higher.

https://scholar.google.com/scholar?hl=n ... BHZt6Oy0EJ


pieces were sung with great recision anlert. 瀾 sometimes when I meet with such apathy on the pur
TTTS TTS SLLLSTTT
JE Roll made a few remarks on the Tonic Sol-fa||..."," J", ought to be active. Mlany of the D. Methol recºmmenline it it is simplicit: il P-||...... was System. One, I ness. The audience appeared highly gratilied witlu tlu know, is doing well. I have lately visited the tttS ikkS:"":""; 點"":"", 1 classes, which are all taught by unprofessional man
Bekijken op search.proquest.com
Verwante artikelen
sciencedirect.com
Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study
David J Ralph, Ian Eardley, Jorg Taubel, Paul Terrill, Tim Holland
The Journal of Sexual Medicine 15 (2), 167-175, 2018
Background
Current treatments for erectile dysfunction (ED) have some limitations.
Aim
This study evaluated the efficacy and tolerability of MED2005, a 0.2% glyceryl trinitrate topical gel, formulated into an enhanced absorption topical delivery system (DermaSys), administered on demand, in the treatment of ED.
Methods
This randomized, double-blinded, placebo-controlled, phase II crossover trial involved 232 men with ED (231 treated, 230 assessed for efficacy) and their partners. After a 4-week run-in period, patients were randomized to 1 of 2 treatment sequences, MED2005-placebo or placebo-MED2005. Each treatment was given for 4 weeks, separated by a 1-week washout interval. Efficacy was assessed by the International Index of Erectile Function (IIEF), the Sexual Encounter Profile, a Global Assessment Questionnaire (GAQ), and specific questions about the onset and offset of action and treatment preferences (patients and partners).
Outcomes
The primary outcome measure was the IIEF erectile function domain (IIEF-EF) score. Other efficacy assessments were secondary outcomes.
Results
The mean baseline IIEF-EF score was 17.1 (SD = 5.7), and this increased to 19.6 (SD = 7.5) after MED2005 treatment and 18.5 (SD = 6.7) after placebo (P = .0132). Overall, 23.1% of patients showed a clinically relevant (≥4-point) increase in IIEF-EF scores after treatment with MED2005 only compared with 14.5% who responded after MED2005 and placebo, 14.0% who responded after placebo only, and 48.4% who did not respond after either treatment (P = .0272). MED2005 also was associated with significant improvements compared with placebo in the other IIEF domains, and this was consistent with patients’ and partners’ responses to the GAQ. For all assessments, significant effects of MED2005 were seen primarily in patients with mild ED. The start of erection was noticed within 5 and 10 minutes in 44.2% and 69.5%, respectively, of all intercourse attempts with MED2005. Patients and partners showed significant preferences for MED2005 over placebo. The most commonly reported adverse events during MED2005 treatment were headache (patients, n = 18 [7.9%]; partners, n = 3 [1.3%]) and nasopharyngitis (patients, n = 13 [5.7%]; partners, n = 2 [0.9%]).
Clinical Implications
These findings suggest that topical glyceryl trinitrate could be a useful treatment option in ED.
Strengths and Limitations
Strengths of this study include the use of a validated outcome measure. Limitations include the use of only 1 dosage.
Conclusion
Further studies are warranted to investigate the efficacy of topical glyceryl trinitrate to include higher doses, thereby improving clinical significance, especially in cases of moderate and severe ED.
Ralph DJ, Eardley I, Taubel J, et al. Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study. J Sex Med 2018;15:167–175.

for all i know they're not the same thing, med3000 was the "placebo gel" in the med2005 trial.
the poor result compared to placebo its because that wasnt a placebo after all

Both are placebo

[Flavio]

It's a scam. I found this article about Med2005, which is basically Med3000.
[...]

I don't think it's a scam but let's wait and see, you may be right.

The fact that it's a placebo is intriguing but they never made a secret of it.

Eroxon is FDA and EMA approved, that's more than enough to get mya attention.

[Flavio]

Everyone please listen: let's keep our eyes open and inform the forum when MED3000 becomes available, so we can try it ASAP.

If it works, great. If it's a scam, we'll spread the word and spare everyone the money.

[tonyareias]

Also if it only works for some, is a victory. But approvals do not lie, is not a scam. Maybe not good as Viagra but do the job for some people.

MED3000 works through a unique evaporative mode of action. MED3000’s combination of volatile components creates a novel action that stimulates nerve sensors in the highly innervated glans penis by a cooling and recovery warming effect, rapidly leading to smooth muscle relaxation, tumescence and erection as shown on the diagram below.

The glans penis is very highly innervated and there are sensors which are reactive to a range of physical sensations, including touch, pressure and temperature. Futura conducted further research and analysis in 2020 which demonstrated the mode of action for MED3000 as shown in the graph. MED3000 generates a rapid cooling and recovery warming action, promoting a sensory stimulation of the nerves on the glans penis leading to fast smooth muscle relaxation, tumescence and erection.

I tried Vitaros gel when released and not worked for me. But for some people it works.

[Flavio]

If you live in Europe or Hong Kong and are interested in EROXON (MED 3000), here are the contact details:

https://www.cooperconsumerhealth.eu/our ... ct-details

There are no US contacts yet.

Please contact the companies in your area and share the info with us, they may accept online orders from overseas.

[Flavio]

I just got a reply from Vemedia Portugal, they don't have any dates yet.

More on this:

www.vemedia.com

[tonyareias]

In Phase III trial data, the gel appeared to work as quickly as ten minutes after application, with results comparable (if less effective overall) to the lowest dose of tadalafil (2.5-5 mg).

This means that in the worst case it will be equivalent to Cialis 2.5-5 mg?

[Brent1]

In Phase III trial data, the gel appeared to work as quickly as ten minutes after application, with results comparable (if less effective overall) to the lowest dose of tadalafil (2.5-5 mg).

This means that in the worst case it will be equivalent to Cialis 2.5-5 mg?

No, it means in the worst case it's less effective than taladafil or even not effective at all.